Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Alrizomadlin is an orally active inhibitor of Mdm2 with IC50 of 3.8 nM and Ki of 1 nM, respectively[1]. Alrizomadlin blocks the interaction of Mdm2 and p53 and induces cell-cycle arrest and Apoptosis in a p53-dependent manner.
説明 | Alrizomadlin is an orally active inhibitor of MDM2 with IC50 of 3.8 nM and Ki of 1 nM, respectively[1]. Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner. |
ターゲット&IC50 | APG-115:3.8 nM |
In vitro | Alrizomadlin (0.001-100 μM) inhibits cell proliferation in a concentration-dependent manner(IC50s: 18.9 nM and 103.5 ± 18.3 nM respectively in AGS and MKN45 cells). Alrizomadlin (0.02-0.2 μM) activates p53 to enhance radiosensitivity in AGS and MKN45 cells and enhances the anti-proliferative effect of radiotherapy at different radiation doses. Stable knockout of p53 abrogates expression of MDM2, p53, p21, PUMA, BAX, Cleaved-caspase3, γH2AX. Alrizomadlin affects progression by inducing cells arrested at G0/G1 phase[3]. Alrizomadlin (0.3 μM-10 μM) leads to a concentration-dependent cell cycle arrest in G2/M phases and decreases S-phase in p53 wide-type cell lines (TPC-1, KTC-1)[4]. |
In vivo | In male BALB/c athymic nude mice with MKN45 cells, Alrizomadlin (100 mg/kg; orally) enhances radiation antitumor effect in gastric adenocarcinoma[3]. |
別名 | AA-115, APG-115 |
分子量 | 642.59 |
分子式 | C34H38Cl2FN3O4 |
CAS No. | 1818393-16-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 90mg/mL (140.1mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Alrizomadlin 1818393-16-6 Apoptosis Mdm2 AA-115 APG-115 Inhibitor inhibitor inhibit